PROspective Registry Of Pancreatic Neuroendocrine Tumors (PROPNET)

Overview

About this study

The purpose of this study is to establish a robust, prospective database to assess longitudinal outcomes for patients with small PNETS as well as assess patient-reported outcomes through virtual distribution of surveys.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Pancreas mass ≤ 20 mm in size

  • Mass localized to the pancreas

  •  

Exclusion Criteria: 

  • Biopsy-proven adenocarcinoma prior to enrollment

  • Confirmed metastatic disease

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/02/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Jad AbiMansour, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions